Clinical Evaluation of Omadacycline for Pulmonary Mycobacterium abscessus Complex Infections: A Subgroup Analysis With a Focus on Macrolide Resistance
Abstract
Background: Pulmonary infections caused by Mycobacterium abscessus complex (MABC) are notoriously difficult to treat due to high levels of mutational and inducible antibiotic resistance. Omadacycline (OMC), an aminomethylcycline antibiotic with both oral and IV formulations, has shown in vitro activity against MABC and may offer a more tolerable alternative to conventional therapies. However, clinical data specific to pulmonary MABC with macrolide resistance remain limited. The aim of this study was to evaluate the clinical and microbiological outcomes of OMC-based therapy in patients with pulmonary MABC infections.
Research question: What are the clinical and microbiological outcomes of OMC-based therapy in patients with pulmonary MABC infections, including those with macrolide resistant isolates?
Study design and methods: This was a retrospective subgroup analysis of a previously published multicenter cohort study conducted across 16 US academic medical centers. Adult patients with pulmonary MABC infections who received OMC for ≥ 72 hours and had ≥ 3 months of follow-up were included. The primary outcome was clinical success at 3, 6, and 12 months, defined as a composite of clinical improvement, survival, continued OMC use, and absence of microbiologic recurrence. Secondary outcomes included sputum culture improvement, outcomes by MABC subspecies and macrolide susceptibility, and adverse drug reactions.
Results: Thirty-five patients were included (68.6% macrolide…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 8 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.